Pharmacotherapies for treatment of cocaine abuse: Preclinical aspects

Journal of Medicinal Chemistry

Volumn 42, Issue 15, 1999, Pages 2721-2736

  Carroll, F Ivy ^a   Howell, Leonard L ^b   Kuhar, Michael J ^b  

^a RTI INTERNATIONAL   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 3 ALLYL 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; 5 METHOXY 1 METHYL 2 PROPYLAMINOTETRALIN; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ALAPROCLATE; APOMORPHINE; BENZATROPINE; BROMOCRIPTINE; CALCIUM CHANNEL BLOCKING AGENT; COCAINE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE UPTAKE INHIBITOR; EMONAPRIDE; FLUOXETINE; HALOPERIDOL; MAZINDOL; METHADONE; METHYLPHENIDATE; NAFADOTRIDE; NALTREXONE; NOMIFENSINE; QUINPIROLE; QUIPAZINE; RACLOPRIDE; RTI 130; RTI 177; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SPIPERONE; TROPARIL; TRYPTOPHAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANOXERINE;

ANIMAL CELL; COCAINE DEPENDENCE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG BINDING; DRUG STRUCTURE; METHADONE TREATMENT; NEUROPATHOLOGY; NONHUMAN; REVIEW; SQUIRREL MONKEY;

ANIMALS; CALCIUM CHANNEL BLOCKERS; COCAINE-RELATED DISORDERS; CORTICOTROPIN-RELEASING HORMONE; DOPAMINE AGENTS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; IMMUNIZATION; NEUROTRANSMITTER AGENTS; RECEPTORS, OPIOID; SEROTONIN AGENTS;

EID: 0033615028     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9706729     Document Type: Review

References (196)

1. Substance Abuse and Mental Health Services Administration National Household Survey on Drug Abuse: Main Findings 1997; Department of Health and Human Services: Washington, DC, 1998.
2. Swan, N. Drug Abuse Cost to Society Set at $97.7 Billion, Continuing Steady Increase Since 1975. NIDA Notes 1998, 13.
3. The Economic Cost of Alcohol and Drug Abuse in the United States; National Clearinghouse for Alcohol and Drug Use, 1992; BKD265.
4. Jaffe, J. H. Drug addiction and drug abuse. In The Pharmacological Basis of Therapeutics; Gilman, A. G., Rall, T. W., Nies, A. S., Taylor, P., Eds.; Pergamon Press: Elmsford, NY, 1990; pp 522-573.
5. Wise, R. A.; Bozarth, M. A. A psychomotor stimulant theory of addiction. Psychol. Rev. 1987, 94, 469-492.
6. Johanson, C. E.; Fischman, M. W. The pharmacology of cocaine related to its abuse. Pharmacol. Rev. 1989, 41, 3-52.
7. Schuster, C. R.; Kuhar, M. J. Pharmacological Aspects of Drug Dependence: Toward an Integrated Neurobehavioral Approach; Springer-Verlag: New York, 1996; Vol. 118.
8. Woolverton, W. L.; Johnson, K. M. Neurobiology of cocaine abuse. Trends Pharmacol. Sci. 1992, 13, 193-200.
9. Hyman, S. E. Addiction to cocaine and amphetamine. Neuron 1996, 16, 901-904.
10. Nestler, E. J. Molecular mechanism of drug addiction. J. Neurosci. 1992, 12, 2439-2450.
11. Dole, V. P.; Nyswander, M. E. A medical treatment for diacetylmorphine (heroin) addiction. J. Am. Med. Assoc. 1965, 193, 646-650.
12. Dole, V. P. Research on addictive behavior. Clin. Invest. Med. 1986, 9, 290-292.
13. Kreek, M. J. Rationale for maintenance pharmacotherapy of opiate dependence. Res. Publ. Assoc. Res. Nerv. Ment. Dis. 1992, 70, 205-230.
14. Rose, J. E.; Behm, F. M.; Westman, E. C. Nicotine-mecamylamine treatment for smoking cessation: The role of pre-cessation therapy. Exp. Clin. Psychopharmacol. 1998, 6, 331-343.
15. O'Malley, S. S.; Jaffe, A. J.; Chang, G.; Schottenfeld, R. S.; Meyer, R. E.; Rounsaville, B. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch. Gen. Psychiatry 1992, 49, 881-887.
16. Volpicelli, J. R.; Alterman, A. I.; Hayashida, M.; O'Brien, C. P. Naltrexone in the treatment of alcohol dependence [see comments]. Arch. Gen. Psychiatry 1992, 49, 876-880.
17. McCance, E. F. Overview of potential treatment medications for cocaine dependence. NIDA Res. Monogr. 1997, 175, 36-72.
18. Nutt, D. J. Addiction: Brain mechanisms and their treatment implications. Lancet 1996, 347, 31-36.
19. O'Brien, C. P. Drug addiction and abuse. In The Pharmacological Basis of Therapeutics, 9th ed.; Gilman, A. G., Rall, T. W., Nies, A. S., Taylor, P., Eds.; McGraw-Hill: New York, 1996; pp 557-577.
20. Mendelson, J. H.; Mello, N. K. Management of cocaine abuse and dependence. N. Engl. J. Med. 1996, 334, 965-972.
21. Witkin, J. M. Pharmacotherapy of cocaine abuse: Preclinical development. Neurosci. Biobehav. Rev. 1994, 18, 121-142.
22. Amara, S. G.; Sonders, M. S. Neurotransmitter transporters as molecular targets for addictive drugs. Drug Alcohol Depend. 1998, 51, 87-96.
23. Klein, M. Research issues related to development of medications for treatment of cocaine addiction. Ann. N. Y. Acad. Sci. 1998, 844 (Neurochemistry of Drugs of Abuse), 75-91.
24. Newman, A. H. Novel dopamine transporter ligands: The state of the art. Med. Chem. Res. 1998, 8, 1-11.
25. Rothman, R. B.; Glowa, J. R. A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development. Mol. Neurobiol. 1995, 11, 1-19.
26. Mello, N. K.; Negus, S. S. Preclinical evaluation of pharmacotherapies for treatment of cocaine and opioid abuse using drug self-administration procedures. Neuropsychopharmacology 1996, 14, 375-424.
27. Landry, D. W. Immunotherapy for cocaine addiction. Sci. Am. 1997, 1997, 42.
28. 3H]WIN 35,428 binding to dopamine uptake sites in vivo more rapidly than mazindol or GBR 12909. Eur. J. Pharmacol. 1991, 198, 203-205.
29. Fleckenstein, A. E.; Kopajtic, T. A.; Boja, J. W.; Carroll, F. I.; Kuhar, M. J. Highly potent cocaine analogues cause long-lasting increases in locomotor activity. Eur. J. Pharmacol. 1996, 311, 109-114.
30. Stathis, M.; Scheffel, U.; Lever, S. Z.; Boja, J. W.; Carroll, F. I.; Kuhar, M. J. Rate of binding of various inhibitors at the dopamine transporter in vivo. Psychopharmacology (Berlin) 1995, 119, 376-384.
31. Gorelick, D. A. The rate hypothesis and agonist substitution approaches to cocaine abuse treatment. Adv. Pharmacol. (San Diego) 1998, 42 (Catecholamines), 995-997.
32. Altman, J.; Everitt, B. J.; Glautier, S.; Markou, A.; Nutt, D.; Oretti, R.; Phillips, G. D.; Robbins, T. W. The biological, social and clinical bases of drug addiction: Commentary and debate. Psychopharmacology (Berlin) 1996, 125, 285-345.
33. Yamamura, H. I.; Enna, S. J.; Kuhar, M. J. Methods in Neurotransmitter Receptor Analysis; Raven Press: New York, 1990.
34. Sahgal, A. Behavioural Neuroscience, A Practical Approach; University Press: Oxford, 1993.
35. Greenshaw, A. J.; Dourish, C. T. Experimental Psychopharmacology; Humana: Totowa, NJ, 1987.
36. Sambrook, J.; Fritsch, E. F.; Maniatis, T. Molecular Cloning: A Laboratory Manual; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 1989.
37. Wise, R. A. Drug-activation of brain reward pathways. Drug Alcohol Depend. 1998, 51, 13-22.
38. Ritz, M. C.; Lamb, R. J.; Goldberg, S. R.; Kuhar, M. J. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 1987, 237, 1219-1223.
39. Kuhar, M. J.; Ritz, M. C.; Boja, J. W. The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci. 1991, 14, 299-302.
40. Koob, G. F.; Bloom, F. E. Cellular and molecular mechanisms of drug dependence. Science 1988, 242, 715-723.
41. Robinson, T.; Barridge, K. C. The neural basis of drug craving: An incentive-sensitization theory of addiction. Brain Res. Rev. 1993, 18, 249-291.
42. Kuhar, M. J.; Pilotte, N. S. Neurochemical changes in cocaine withdrawal. Trends Pharmacol. Sci. 1996, 17, 260-264.
43. Baxter, B. L.; Gluckman, M. I.; Stein, L.; Scerni, R. A. Self-injection of apomorphine in the rat: Positive reinforcement by a dopamine receptor stimulant. Pharmacol. Biochem. Behav. 1974, 2, 387-391.
44. Howell, L. L.; Byrd, L. D. Characterization of the effects of cocaine and GBR 12909, a dopamine uptake inhibitor, on behavior in the squirrel monkey. J. Pharmacol. Exp. Ther. 1991, 258, 178-185.
45. Woolverton, W. L.; Goldberg, L. I.; Ginos, J. Z. Intravenous self-administration of dopamine receptor agonists by rhesus monkeys. J. Pharmacol. Exp. Ther. 1984, 230, 678-683.
46. Yokel, R. A.; Wise, R. A. Amphetamine-type reinforcement by dopaminergic agonists in the rat. Psychopharmacology (Berlin) 1978, 58, 289-296.
47. Melia, K. F.; Spealman, R. D. Pharmacological characterization of the discriminative-stimulus effects of GBR 12909. J. Pharmacol Exp. Ther. 1991, 258, 626-632.
48. Witkin, J. M.; Nichols, D. E.; Terry, P.; Katz, J. L. Behavioral effects of selective dopaminergic compounds in rats discriminating cocaine injections. J. Pharmacol. Exp. Ther. 1991, 257, 706-713.
49. Jarbe, T. U. Discriminative stimulus properties of cocaine. Effects of apomorphine, haloperidol, procaine and other drugs. Neuropharmacology 1984, 23, 899-907.
50. McKenna, M. L.; Ho, B. T. The role of dopamine in the discriminative stimulus properties of cocaine. Neuropharmacology 1980, 19, 297-303.
51. De Wit, H.; Wise, R. A. Blockade of cocaine reinforcement in rats with the dopamine receptor blocker pimozide, but not with the noradrenergic blockers phentolamine or phenoxybenzamine. Can. J. Psychol. 1977, 31, 195-203.
52. Woolverton, W. L. Effects of a D1 and a D2 dopamine antagonist on the self-administration of cocaine and piribedil by rhesus monkeys. Pharmacol. Biochem. Behav. 1986, 24, 531-535.
53. Scheel-Kruger, J.; Braestrup, C.; Nielson, M.; Golembiowska, K.; Mogilnicka, E. Cocaine: discussion on the role of dopamine in the biochemical mechanism of action. In Cocaine and Other Stimulants; Ellinwood, E. H., Jr., Kilbey, M. M., Eds.; Plenum Press: New York, 1977; pp 273-407.
54. Barrett, R. L.; Appel, J. B. Effects of stimulation and blockade of dopamine receptor subtypes on the discriminative stimulus properties of cocaine. Psychopharmacology 1989, 99, 13-16.
55. Colpaert, F. C.; Niemegeers, C. J. E.; Janssen, P. A. J. Discriminative stimulus properties of cocaine. Neuropharmacological characteristics derived from stimulus generalization experiments. Pharmacol. Biochem. Behav. 1978, 10, 535-546.
56. Kleven, M. S.; Anthony, E. W.; Goldberg, L. I.; Woolverton, W. L. Blockade of the discriminative stimulus effects of cocaine in rhesus monkeys with the D1 dopamine antagonist SCH 23390. Psychopharmacology 1988, 95, 427-429.
57. Bergman, J.; Spealman, R. D. Behavioral effects of histamine H1 antagonists: Comparison with other drugs and modification by haloperidol. J. Pharmacol. Exp. Ther. 1988, 245, 471-478.
58. Howell, L. L.; Byrd, L. D. Enhanced sensitivity to the behavioral effects of cocaine after chronic administration of D2-selective dopamine antagonists in the squirrel monkey. J. Pharmacol. Exp. Ther. 1992, 262, 907-915.
59. Spealman, R. D. Antagonism of behavioral effects of cocaine by selective dopamine receptor blockers. Psychopharmacology 1990, 101, 142-145.
60. Schultz, W.; Dayan, P.; Montague, P. R. A neural substrate of prediction and reward. Science 1997, 275, 1593-1599.
61. Bergman, J.; Madras, B. K.; Johnson, S. E.; Spealman, R. D. Effects of cocaine and related drugs in nonhuman primates. III. Self-administration by squirrel monkeys. J. Pharmacol. Exp. Ther. 1989, 251, 150-155.
62. Goeders, N. E.; Smith, J. E. Reinforcing properties of cocaine in the medical prefrontal cortex: Primary action on presynaptic dopaminergic terminals. Pharmacol. Biochem. Behav. 1986, 25, 191-199
63. Madras, B. K.; Elmaleh, D. R.; Meltzer, P. C.; Liang, A. Y.; Brownell, G. L.; Brownell, A. L. Positron emission tomography of cocaine binding sites on the dopamine transporter. NIDA Res. Monogr. 1994, 138, 57-69.
64. Woolverton, W. L.; Kleven, M. S. Multiple dopamine receptors and the behavioral effects of cocaine. NIDA Res. Monogr. 1988, 88, 160-184.
65. Carroll, F. I.; Lewin, A. H.; Boja, J. W.; Kuhar, M. J. Cocaine receptor: Biochemical characterization and structure-activity relationships for the dopamine transporter. J. Med. Chem. 1992, 35, 969-981.
66. Carroll, F. I.; Lewin, A. H.; Kuhar, M. J. Dopamine Transporter Uptake Blockers: Structure-Activity Relationships. In Neurotransmitter Transporters: Structure, Function, and Regulation; Reith, M. E. A., Ed.; Humana: Totowa, NJ, 1997; pp 263-295.
67. Bennett, B. A.; Wichems, C. H.; Hollingsworth, C. K.; Davies, H. M. L.; Thornley, C.; Sexton, T.; Childers, S. R. Novel 2-substituted cocaine analogues: Uptake and ligand binding studies at dopamine, serotonin and norepinephrine transport sites in the rat brain. J. Pharmacol. Exp. Ther. 1995, 272, 1176-1186.
68. Meltzer, P. C.; Liang, A. Y.; Madras, B. K. The discovery of an unusually selective and novel cocaine analog: Difluoropine. Synthesis and inhibition of binding at cocaine recognition sites. J. Med. Chem. 1994, 37, 2001-2010.
69. Deutsch, H. M.; Shi, Q.; Gruszecka-Kowalik, E.; Schweri, M. M. Synthesis and pharmacology of potential cocaine antagonists. 2. Structure-activity relationship studies of aromatic ring-substituted methylphenidate analogues. J. Med. Chem. 1996, 39, 1201-1209.
70. Davies, H. M. L.; Saikali, E.; Sexton, T.; Childers, S. R. Novel 2-substituted cocaine analogues: Binding properties at dopamine transport sites in rat striatum. Eur. J. Pharmacol. - Mol. Pharmacol. Sec. 1993, 244, 93-97.
71. Van der Zee, P.; Koger, H. S.; Gootjes, J.; Hespe, W. Aryl 1,4-dialk(en)ylpiperazines as selective and very potent inhibitors of dopamine uptake. Eur. J. Med. Chem. 1980, 15, 363-370.
72. Wang, S.; Gao, Y.; Laruelle, M.; Baldwin, R. M.; Scanley, B. E.; Innis, R. B.; Neumeyer, J. L. Enantioselectivity of cocaine recognition sites: binding of (1S)-and (1R)-2β-carbomethoxy-3β-(4-iodophenyl)tropane (β-CIT) to monoamine transporters. J. Med. Chem. 1993, 36, 1914-1917.
73. Kline, R. H., Jr.; Wright, J.; Fox, K. M.; Eldefrawi, M. E. Synthesis of 3-arylecgonine analogues as inhibitors of cocaine binding and dopamine uptake. J. Med. Chem. 1990, 33, 2024-2027.
74. Simoni, D.; Stoelwinder, J.; Kozikowski, A. P.; Johnson, K. M.; Bergmann, J. S.; Ball, R. G. Methoxylation of cocaine reduces binding affinity and produces compounds of differential binding and dopamine uptake inhibitory activity: Discovery of a weak cocaine "antagonist". J. Med. Chem. 1993, 36, 3975-3977.
75. Goodman, M. M.; Kung, M.-P.; Kabalka, G. W.; Kung, H. F.; Switzer, R. Synthesis and characterization of radioiodinated N-(3-iodopropen-1-yl)-2β-carbomethoxy-3β-(4-chlorophenyl)tropanes: Potential dopamine reuptake site imaging agents. J. Med. Chem. 1994, 37, 1535-1542.
76. Newman, A. H.; Allen, A. C.; Izenwasser, S.; Katz, J. L. Novel 3α-(diphenylmethoxy)tropane analogues: Potent dopamine uptake inhibitors without cocaine-like behavioral profiles. J. Med. Chem. 1994, 37, 2258-2261.
77. Glowa, J. R.; Wojnicki, F. H. E.; Matecka, D.; Bacher, J. D.; Mansbach, R. S.; Balster, R. L.; Rice, K. C. Effects of dopamine reuptake inhibitors on food-and cocaine-maintained responding: I. Dependence on unit dose of cocaine. Exp. Clin. Psychopharmacol. 1995, 3, 219-231.
78. Nader, M. A.; Grant, K. A.; Davies, H. M.; Mach, R. H.; Childers, S. R. The reinforcing and discriminative stimulus effects of the novel cocaine analogue 2β-propanoyl-3β-(4-tolyl)-tropane in rhesus monkeys. J. Pharmacol Exp. Ther. 1997, 280, 541-550.
79. Kuhar, M. J.; Carroll, F. I.; Dworkin, S.; Howell, L.; Hunter, R.; McGirr, K. Pharmacotherapy of cocaine abuse with RTI-113. 59th Annual Scientific Meeting of the CPDD, Nashville, TN, 1997,.
80. Kleven, M. S.; Woolverton, W. L. Effects of bromocriptine and desipramine on behavior maintained by cocaine or food presentation in rhesus monkeys. Psychopharmacology 1990, 101, 208-213.
81. Grech, D. M.; Spealman, R. D.; Bergman, J. Self-administration of D1 receptor agonists by squirrel monkeys. Psychopharmacology (Berlin) 1996, 125, 97-104.
82. Warner, E. A.; Kosten, T. R.; O'Connor, P. G. Pharmacotherapy for Opioid and Cocaine Abuse. Med. Clin. North Am. 1997, 81, 909-925.
83. Caine, S. B.; Koob, G. F. Modulation of cocaine self-administration in the rat through D-3 dopamine receptors. Science 1993, 260, 1814-1816.
84. Self, D. W.; Barnhart, W. J.; Lehman, D. A.; Nestler, E. J. Opposite modulation of cocaine-seeking behavior by D1-and D2-like dopamine receptor agonists. Science 1996, 271, 1586-1589.
85. Slusher, B. S.; Tiffany, C. W.; Olkowski, J. L.; Jackson, P. F. Use of identical assay conditions for cocaine analogue binding and dopamine uptake to identify potential cocaine antagonists. Drug Alcohol Depend. 1997, 48, 43-50.
86. Kleven, M. S.; Woolverton, W. L. Effects of continuous infusion of SCH 23390 on cocaine-or food-maintained behavior in rhesus monkeys. Behav. Pharmacol. 1990, 1, 365-373.
87. Katz, J. L.; Witkin, J. M. Behavioral effects of cocaine alone and in combination with selective dopamine antagonists in the squirrel monkey. Psychopharmacology 1991, 103, 33-40.
88. Spealman, R. D.; Bergman, J.; Madras, B. K.; Melia, K. F. Discriminative stimulus effects of cocaine in squirrel monkeys: Involvement of dopamine receptor subtypes. J. Pharmacol. Exp. Ther. 1991, 258, 945-953.
89. Vanover, K. E.; Kleven, M. S.; Woolverton, W. L. Blockade of the discriminative stimulus effects of cocaine in rhesus monkeys with the D1 dopamine antagonists SCH-39166 and A-66359. Behav. Pharmacol. 1991, 2, 151-159.
90. Wise, R. A.; Newton, P.; Leeb, K.; Burnette, B.; Pocock, D.; Justice, J. B., Jr. Fluctuations in nucleus accumbens dopamine concentration during intravenous cocaine self-administration in rats. Psychopharmacology (Berlin) 1995, 120, 10-20.
91. Newton, A. P.; Justice, J. B., Jr. Temporal response of microdialysis probes to local perfusion of dopamine and cocaine followed with one-minute sampling. Anal. Chem. 1994, 66, 1468-1472.
92. Kalivas, P. W. Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Res. Brain Res. Rev. 1993, 18, 75-113.
93. Koob, G. F.; Le, H. T.; Creese, I. The D1 dopamine receptor antagonist SCH 23390 increases cocaine self-administration in the rat. Neurosci. Lett. 1987, 79, 315-320.
94. Corrigall, W. A.; Coen, K. M. Cocaine self-administration is increased by both D1 and D2 dopamine antagonists. Pharmacol. Biochem. Behav. 1991, 39, 799-802.
95. Bergman, J.; Hamien, J. G.; Spealman, R. D. Antagonism of cocaine self-administration by selective dopamine D1 and D2 antagonists. Behav. Pharmacol. 1990, 1, 355-363.
96. Britton, D. R.; Curzon, P.; Mackenzie, R. G.; Kebabian, J. W.; Williams, J. E.; Kerkman, D. Evidence for involvement of both D1 and D2 receptors in maintaining cocaine self-administration. Pharmacol. Biochem. Behav. 1991, 39, 911-915.
97. Richardson, N. R.; Piercey, M. F.; Svensson, K.; Collins, R. J.; Myers, J. E.; Roberts, D. C. S. Antagonism of cocaine self-administration by the preferential dopamine autoreceptor antagonist, (+)-AJ 76. Brain Res. 1993, 619, 15-21.
98. Levant, B. The D3 dopamine receptor: Neurobiology and potential clinical relevance. Pharmacol. Rev. 1997, 49, 231-252.
99. Sautel, F.; Griffon, N.; Sokoloff, P.; Schwartz, J. C.; Launay, C.; Simon, P.; Costentin, J.; Schoenfelder, A.; Garrido, F.; Mann, A.; Wermuth, C. G. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents. J. Pharmacol. Exp. Ther. 1995, 275, 1239-1246.
100. Wolf, W. A.; Kuhn, D. M. Cocaine and serotonin neurochemistry. Neurochem. Int. 1991, 18, 33-38.
101. Ritz, M. C.; Kuhar, M. J. Monoamine uptake inhibition mediates amphetamine self-administration: comparison with cocaine. J. Pharmacol. Exp. Ther. 1989, 248, 1010-1017.
102. Woods, J. H.; Tessel, R. E. Fenfluramine: Amphetamine congener that fails to maintain drug-taking behavior in the rhesus monkey. Science 1974, 185, 706-713.
103. Vanover, K. E.; Nader, M. A.; Woolverton, W. L. Evaluation of the discriminative stimulus and reinforcing effects of sertraline in rhesus monkeys. Pharmacol. Biochem. Behav. 1992, 41, 789-793.
104. Howell, L. L.; Byrd, L. D. Serotonergic modulation of the behavioral effects of cocaine in the squirrel monkey. J. Pharmacol. Exp. Ther. 1995, 275, 1551-1559.
105. Carroll, M. E.; Loc, S. T.; Asencio, M.; Krugh, R. Fluoxetine reduces intravenous cocaine self-administration in rats. Pharmacol. Biochem. Behav. 1990, 35, 237-244.
106. Carroll, M. E.; Lac, S. T.; Asencio, M.; Kragh, R. Intravenous cocaine self-administration in rats is reduced by dietary L-tryptophan. Psychopharmacology 1990, 100, 293-300.
107. Richardson, N. R.; Roberts, D. C. S. Fluoxetine pretreatment reduces breaking points on a progressive ratio schedule reinforced by intravenous cocaine self-administration in the rat. Life Sci. 1991, 49, 833-840.
108. Howell, L. L.; Czoty, P. W.; Byrd, L. D. Pharmacological interactions between serotonin and dopamine on behavior in the squirrel monkey. Psychopharmacology (Berlin) 1997, 131, 40-48.
109. Dray, A.; Davies, J.; Oakley, N. R.; Tongroach, P.; Vellucci, S. The dorsal and medial raphe projections to the substantia nigra in the rat: electrophysiological, biochemical and behavioural observations. Brain Res. 1978, 151, 431-442.
110. Giambalvo, C. T.; Snodgrass, S. R. Biochemical and behavioral effects of serotonin neurotoxins on the nigrostriatal dopamine system: comparison of injection sites. Brain Res. 1978, 152, 555-566.
111. Kelland, M. D.; Freeman, A. S.; Chiodo, L. A. Serotonergic afferent regulation of the basic physiology and pharmacological responsiveness of nigrostriatal dopamine neurons. J. Pharmacol. Exp. Ther. 1990, 253, 803-811.
112. Fibiger, H. C.; Miller, J. J. An anatomical and electrophysiological investigation of the serotonergic projection from the dorsal raphe nucleus to the substantia nigra in the rat. Neuroscience 1977, 2, 975-987.
113. Ugedo, L.; Grenhoff, J.; Svensson, T. H. Ritanserin, a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology 1989, 98, 45-50.
114. Reith, M. E. 5-HT3 receptor antagonists attenuate cocaine-induced locomotion in mice. Eur. J. Pharmacol. 1990, 186, 327-330.
115. Svingos, A. L.; Hitzemann, R. 5-HT3 receptor antagonists block cocaine-induced locomotion via a PCPA-sensitive mechanism. Pharmacol. Biochem. Behav. 1992, 43, 871-879.
116. Van de Hoek, G. A.; Cooper, S. J. Evidence that ondansetron, a selective 5-HT3 antagonist reduces cocaine's psychomotor stimulant effects in the rat. Psychopharmacology 1990, 101, S59.
117. Lane, J. D.; Pickering, C. L.; Hooper, M. L.; Fagan, K.; Tyers, M. B.; Emmett-Oglesby, M. W. Failure of ondansetron to block the discriminative or reinforcing stimulus effects of cocaine in the rat. Drug Alcohol Depend. 1992, 30, 151-162.
118. Lacosta, S.; Roberts, D. C. MDL 72222, ketanserin, and methysergide pretreatments fail to alter breaking points on a progressive ratio schedule reinforced by intravenous cocaine. Pharmacol. Biochem. Behav. 1993, 44, 161-165.
119. Paris, J. M.; Cunningham, K. A. Serotonin 5-HT3 antagonists do not alter the disciminative stimulus properties of cocaine. Psychopharmacology 1991, 104, 475-478.
120. Kalivas, P. W.; Alesdatter, J. E. Involvement of N-methyl-D-aspartate receptor stimulation in the ventral tegmental area and amygdala in behavioral sensitization to cocaine. J. Pharmacol. Exp. Ther. 1993, 267, 486-495.
121. Schenk, S.; Valadez, A.; McNamara, C.; House, D. T.; Higley, D.; Bankson, M. G.; Gibbs, S.; Horger, B. A. Development and expression of sensitization to cocaine's reinforcing properties: role of NMDA receptors. Psychopharmacology 1993, 111, 332-338.
122. Karler, R.; Calder, L. D. Excitatory amino acids and the actions of cocaine. Brain Res. 1992, 582, 143-146.
123. Pulvirenti, L.; Swerdlow, N. R.; Koob, G. F. Nucleus accumbens NMDA antagonist decreases locomotor activity produced by cocaine, heroin or accumbens dopamine but not caffeine. Pharmacol. Biochem. Behav. 1991, 40, 841-845.
124. Seidleck, B. K.; Thurkauf, A.; Witkin, J. M. Evaluation of ADCI against convulsant and locomotor stimulant effects of cocaine: Comparison with the structural analogues dizocilpine and carbamazepine. Pharmacol. Biochem. Behav. 1994, 47, 839-844.
125. Witkin, J. M. Blockade of the locomotor stimulant effects of cocaine and methamphetamine by glutamate antagonists. Life Sci. 1993, 53, PL405-PL410.
126. Schenk, S.; Valadez, A.; Worley, C. M.; McNamara, C. Blockade of the acquisition of cocaine self-administration by the NMDA antagonist MK-801 (dizocilpine). Behav. Pharmacol. 1993, 4, 652-659.
127. Ranaldi, R.; French, E.; Roberts, D. C. Systemic pretreatment with MK-801 (dizocilpine) increases breaking points for self-administration of cocaine on a progressive-ratio schedule in rats. Psychopharmacology (Berlin) 1996, 128, 83-88.
128. Pierce, R. C.; Meil, W. M.; Kalivas, P. W. The NMDA antagonist, dizocilpine, enhances cocaine reinforcement without influencing mesoaccumbens dopamine transmission. Psychopharmacology (Berlin) 1997, 133, 188-195.
129. Kantak, K. M.; Edwards, M. A.; O'Connor, T. P. Modulation of the discriminative stimulus and rate-altering effects of cocaine by competitive and noncompetitive N-methyl-D-aspartate antagonists. Pharmacol. Biochem. Behav. 1998, 59, 159-169.
130. Pap, A.; Bradberry, C. W. Excitatory amino acid antagonists attenuate the effects of cocaine on extracellular dopamine in the nucleus accumbens. J. Pharmacol. Exp. Ther. 1995, 274, 127-133.
131. Mash, D. C.; Kovera, C. A.; Buck, B. E.; Norenberg, M. D.; Shapshak, P.; Hearn, W. L.; Sanchez-Ramos, J. Medication development of ibogaine as a pharmacotherapy for drug dependence. Ann. N. Y. Acad. Sci. 1998, 844 (Neurochemistry of Drugs of Abuse), 274-292.
132. Popik, P.; Layer, R. T.; Fossom, L. H.; Benveniste, M.; Geter-Douglass, B.; Witkin, J. M.; Skolnick, P. NMDA antagonist properties of the putative antiaddictive drug, ibogaine. J. Pharmacol. Exp. Ther. 1995, 275, 753-760.
133. Chen, K.; Kokate, T. G.; Donevan, S. D.; Carroll, F. I.; Rogawski, M. A. Ibogaine block of the NMDA receptor: In vitro and in vivo studies. Neuropharmacology 1996, 35, 423-431.
134. Layer, R. T.; Skolnick, P.; Bertha, C. M.; Bandarage, U. K.; Kuehne, M. E.; Popik, P. Structurally modified ibogaine analogues exhibit differing affinities for NMDA receptors. Eur. J. Pharmacol. 1996, 309, 159-165.
135. Shoaib, M.; Shippenberg, T. S.; Goldberg, S. R.; Schindler, C. W. Behavioral studies with the glycine partial agonist (+)-HA966 on cocaine-induced locomotor activity and reinforcement. Behav. Pharmacol. 1995, 6, 568-576.
136. Shimosato, K.; Marley, R. J.; Saito, T. Differential effects of NMDA receptor and dopamine receptor antagonists on cocaine toxicities. Pharmacol. Biochem. Behav. 1995, 51, 781-788.
137. Witkin, J. M.; Tortella, F. C. Modulators of N-methyl-D-aspartate protect against diazepam-or phenobarbital-resistant cocaine convulsions. Life Sci. 1991, 48, PL51-PL56.
138. Dewey, S. L.; Chaurasia, C. S.; Chen, C. E.; Volkow, N. D.; Clarkson, F. A.; Porter, S. P.; Straughter-Moore, R. M.; Alexoff, D. L; Tedeschi, D.; Russo, N. B.; Fowler, J. S.; Brodie, J. D. GABAergic attenuation of cocaine-induced dopamine release and locomotor activity. Synapse 1997, 25, 393-398.
139. Morgan, A. E.; Dewey, S. L. Effects of pharmacologic increases in brain GABA levels on cocaine-induced changes in extracellular dopamine. Synapse 1998, 28, 60-65.
140. Roberts, D. C. S.; Andrews, M. M. Baclofen suppression of cocaine self-administration: Demonstration using a discrete trials procedure. Psychopharmacology (Berlin) 1997, 131, 271-277.
141. Cameron, D. L.; Williams, J. T. Cocaine inhibits GABA release in the VTA through endogenous 5-HT. J. Neurosci. 1994, 14, 6763-6767.
142. Dewey, S. L.; Smith, G. S.; Logan, J.; Brodie, J. D.; Yu, D. W.; Ferrieri, R. A.; King, P. T.; MacGregor, R. R.; Martin, T. P.; Wolf, A. P.; et al. GABAergic inhibition of endogenous dopamine release measured in vivo with 11C-raclopride and positron emission tomography. J. Neurosci. 1992, 12, 3773-3780.
143. Ling, W.; Shoptaw, S.; Majewska, D. Baclofen as a cocaine anti-craving medication: A preliminary clinical study. Neuropsychopharmacology 1998, 18, 403-404.
144. Dewey, S. L.; Morgan, A. E.; Ashby, C. R.; Horan, B.; Kushner, S. A.; Logan, J.; Volkow, N. D.; Fowler, J. S.; Gardner, E. L.; Brodie, J. D. A novel stretegy for the treatment of cocaine addiction. Synapse 1998, 30, 119-129.
145. Herz, A. Endogenous opioid systems and alcohol addiction. Psychopharmacology (Berlin) 1997, 129, 99-111.
146. Spanagel, R.; Herz, A.; Shippenberg, T. A. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 2046-2050.
147. Kreek, M. J. Cocaine, dopamine, and the endogenous opioid system. J. Addictive Dis. 1996, 15, 73-96.
148. Reid, L. D.; Hubbell, C. L.; Glick, S. D.; Boswell, K. J. Initial analyses of naltriben, a delta opioid receptor antagonist, as a putative medicine for treating cocaine abuse. Exp. Clin. Psychopharmacol. 1996, 4, 271-284.
149. Hubbell, C. L.; Reid, L. D. Antagonism at delta opioid receptors blocks cocaine's, but not morphine's, enhancement of responding for intercranial stimulation. Exp. Clin. Psychopharmacol. 1995, 3, 123-128.
150. de Vries, T. J.; Babovic-Vuksanovic, D.; Elmer, G.; Shippenberg, T. S. Lack of Involvement of δ-opioid Receptors in mediating the rewarding effects of cocaine. Psychopharmacology 1995, 120, 442-448.
151. Negus, S. S.; Mello, N. K.; Portoghese, P. S.; Lukas, S. E.; Mendelson, J. H. Role of delta opioid receptors in the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys. J. Pharmacol. Exp. Ther. 1995, 273, 1245-1256.
152. Glick, S. D.; Maisonneuve, I. M.; Raucci, J.; Archer, S. Kappa opioid inhibition of morphine and cocaine self-administration in rats. Brain Res. 1995, 681, 147-152.
153. Mello, N. K.; Negus, S. S. Effects of kappa opioid agonists on cocaine-and food-maintained responding by rhesus monkeys. J. Pharmacol. Exp. Ther. 1998, 286, 812-824.
154. Comer, S. D.; Lac, S. T.; Wyvell, C. L.; Carroll, M. E. Combined effects of buprenorphine and a nondrug alternative reinforcer on i.v. cocaine self-administration in rats maintained under FR schedules. Psychopharmacology (Berlin) 1996, 125, 355-360.
155. Tech, S. K.; Melle, N. K.; Mendelson, J. H.; Kuehnle, J.; Gastfriend, D. R. Buprenorphine effects on heroin-and cocaine-induced subjective responses by drug dependent men. J. Clin. Pharmacol. 1994, 14, 15-77.
156. Schottenfeld, R. S.; Pakes, J.; Ziedonis, D.; Kosten, T. R. Buprenorphine: Dose-related effect on cocaine and opioid use in cocaine-abusing opioid-dependent humans. Biol. Psychiatry 1993, 34, 66-74.
157. Ramsey, N. F.; Mirjam, A. F. M.; Gerrits, J. M. V. R. Naltrexone affects cocaine self-administration in naive rats through the ventral tegmental area rather than dopaminergic target regions. Neuropsychopharmacology 1999, 9, 93-99.
158. Ramsey, N. F.; Van Ree, J. M. Chronic pretreatment with naltrexone facilitates acquisition of intravenous cocaine self-administration in rats. Eur. Neuropsychopharmacol. 1990, 1, 55-61.
159. Kuzmin, A. V.; Semenova, S.; Gerrits, M. A.; Zvartau, E. E.; Van Ree, J. M. Kappa-opioid receptor agonist U50,488H modulates cocaine and morphine self-administration in drug-naive rats and mice. Eur. J. Pharmacol. 1997, 321, 265-271.
160. Kuzmin, A. V.; Gerrits, M. A.; Van Ree, J. M. Kappa-opioid receptor blockade with nor-binaltorphimine modulates cocaine self-administration in drug-naive rats. Eur. J. Pharmacol. 1998, 358, 197-202.
161. Sharkley, J.; Glen, K. A.; Wolfe, S.; Kuhar, M. J. Cocaine binding at σ receptors. Eur. J. Pharmacol. 1988, 149, 171-174.
162. Ujike, H.; Kuroda, S.; Otsuki, S. σ Receptor antagonists block the development of sensitization to cocaine. Eur. J. Pharmacol. 1996, 296, 123-128.
163. Menkel, M.; Terry, P.; Pontecorvo, M.; Katz, J. L.; Witkin, J. M. Selective σ ligands attenuate cocaine-induced toxicity and locomotor stimulation. Eur. J. Pharmacol. 1991, 201, 251-252.
164. Tom, S. W. In Sigma Receptors; Itzhak, Y., Ed.; Academic Press Ltd.: London, 1994.
165. McCracken, K. A.; Bowen, W. D.; Matsumoto, R. R. Novel σ receptor ligands attenuate the locomotor stimultory effects of cocaine. Eur. J. Pharmacol. 1999, 365, 35-38.
166. Pani, L.; Kuzmin, A.; Diana, M.; De Montis, G.; Gessa, G. L.; Rossetti, Z. L. Calcium receptor antagonists modify cocaine effects in the central nervous system differently. Eur. J. Pharmacol. 1990, 190, 217-221.
167. Calcagnetti, D. J.; Keck, B. J.; Quatrella, L. A.; Schechter, M. D. Blockade of cocaine-induced conditioned place preference: relevance to cocaine abuse therapeutics. Life Sci. 1995, 56, 475-483.
168. Schechter, M. D. Cocaine discrimination is attenuated by isradipine and CGS 10746B. Pharmacol. Biochem. Behav. 1993, 44, 661-664.
169. Kuzmin, A.; Zvartau, E.; Gessa, G. L.; Martellotta, M. C.; Fratta, W. Calcium antagonists isradipine and nimodipine suppress cocaine and morphine intravenous self-administration in drug-naive mice. Pharmacol. Biochem. Behav. 1992, 41, 497-500.
170. Martellotta, M. C.; Kuzmin, A.; Muglia, P.; Gessa, G. L.; Fratta, W. Effects of the calcium antagonist isradipine on cocaine intravenous self-administration in rats. Psychopharmacology (Berlin) 1994, 113, 378-380.
171. 1 receptor: Design of small molecule inhibitors, receptor subtypes and clinical indications. Curr. Pharm. Des. 1999.
172. Sarnyai, Z. Neurobiology of stress and cocaine addiction. Studies on corticotropin-releasing factor in rats, monkeys, and humans. Ann. N. Y. Acad. Sci. 1998, 851, 371-387.
173. Shaham, Y.; Erb, S.; Leung, S.; Buczek, Y.; Stewart, J. CP-154,-526, a selective, non-peptide antagonist of the corticotropin-releasing factor1 receptor attenuates stress-induced relapse to drug seeking in cocaine-and heroin-trained rats. Psychopharmacology (Berlin) 1998, 137, 184-190.
174. Arvanitis, A. G.; Gilligan, P. J.; Chorvat, R. J.; Cheeseman, R. S.; Christos, T. E.; Bakthavatchalam, R.; Beck, J. P.; Cocuzza, A. J.; Hobbs, F. W.; Wilde, R. G.; Arnold, C.; Chidester, D.; Curry, M.; He, L.; Hollis, A.; Klaczkiewicz, J.; Krenitsky, P. J.; Rescinito, J. P.; Scholfield, E.; Culp, S.; De Souza, E. B.; Fitzgerald, L.; Grigoriadis, D.; Tam, S. W.; Wong, Y. N.; Huang, S. M.; Shen, H. L. Non-peptide corticotropin-releasing hormone antagonists: Syntheses and structure-activityrelationships of 2-anilinopyrimidines and -triazines. J. Med. Chem. 1999, 42, 805-818.
175. Hodge, C. N.; Aldrich, P. E.; Wasserman, Z. R.; Fernandez, C. H.; Nemeth, G. A.; Arvanitis, A.; Cheeseman, R. S.; Chorvat, R. J.; Ciganek, E.; Christos, T. E.; Gilligan, P. J.; Krenitsky, P.; Scholfield, E.; Strucely, P. Corticotropin-releasing hormone receptor antagonists: Framework design and synthesis guided by ligand conformational studies. J. Med. Chem. 1999, 42, 819-832.
176. Chorvat, R. J.; Bakthavatchalam, R.; Beck, J. P.; Gilligan, P. J.; Wilde, R. G.; Cocuzza, A. J.; Hobbs, F. W.; Cheeseman, R. S.; Curry, M.; Rescinito, J. P.; Krenitsky, P.; Chidester, D.; Yarem, J. A.; Klaczkiewicz, J. D.; Hodge, C. N.; Aldrich, P. E.; Wasserman, Z. R.; Fernandez, C. H.; Zaczek, R.; Fitzgerald, L. W.; Huang, S. M.; Shen, H. L.; Wong, Y. N.; Chien, B. M.; Quon, C. Y.; Arvanitis, A. Synthesis, corticotropin-releasing factor receptor binding affinity, and pharmacokinetic properties of triazolo-, imidazo-, and pyrrolopyrimidines and -pyridines. J. Med. Chem. 1999, 42, 833-848.
177. Fox, B. S.; Kautak, K. M.; Edwards, M. A.; Black, K. M.; Bollinger, B. K.; Botka, A. J.; French, T. L.; Thompson, T. L.; Schad, V. C.; Greenstein, J. L.; Gefter, M. L.; Exley, M. A.; Swain, P. A.; Briner, T. J. Efficacy of a therapeutic cocaine vaccine in rodent models. Nature Med. 1996, 2, 1129-1132.
178. Fox, B. S. Development of therapeutic vaccine for the treatment of cocaine addiction. Drug Alcohol Depend. 1997, 48, 153-158.
179. Landry, D. W.; Zhao, K.; Yang, G. X.-Q.; Glickman, M.; Georgiadis, T. M. Antibody-catalyzed degradation of cocaine. Science 1993, 259, 1899-1901.
180. Mets, B.; Winger, G.; Cabrera, C.; Seo, S.; Jamdar, S.; Yang, G.; Zhao, K.; Briscoe, R. J.; Almonte, R.; Woods, J. H.; Landry, D. W. A catalytic antibody against cocaine prevents cocaine's reinforcing and toxic effects in rats. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 10176-10181.
181. Carmona, G. N.; Schindler, C. W.; Shoaib, M.; Jufer, R.; Cone, E. J.; Goldberg, S. R.; Greig, N. H.; Yu, Q.-S.; Gorelick, D. A. Attenuation of cocaine-induced locomotor activity by butyryl-cholinesterase. Exp. Clin. Psychopharmacol. 1998, 6, 274-279.
182. Carrera, M. R.; Ashley, J. A.; Parsons, L. H.; Wirsching, P.; Koob, G. F.; Janda, K. D. Suppression of psychoactive effects of cocaine by active immunization. Nature 1995, 378, 727-730.
183. Batki, S. L.; Manfredi, L. B.; Jacob, P.; Jones, R. T. Fluoxetine for cocaine dependence in methadone maintenance: quantitative plasma and urine cocaine/benzoylecgonine concentrations. J. Clin. Psychopharmacol. 1993, 13, 243-250.
184. Berger, S. P.; Hall, S.; Mickalian, J. D.; Reid, M. S.; Crawford, C. A.; Delucchi, K.; Carr, K.; Hall, S. Haloperidol antagonism of cue-elicited cocaine craving. Lancet 1996, 347, 504-508.
185. Cline, E. J.; Scheffel, U.; Boja, J. W.; Carroll, F. I.; Katz, J. L.; Kuhar, M. J. Behavioral effects of novel cocaine analogues: A comparison with in vivo receptor binding potency. J. Pharmacol. Exp. Ther. 1992, 260, 1174-1179.
186. Vaugeois, J. M.; Bonnet, J. J.; DuterteBoucher, D.; Costentin, J. In vivo occupancy of the striatal dopamine uptake complex by various inhibitors does not predict their effects on locomotion. Eur. J. Pharmacol. 1993, 230, 195-201.
187. Rothman, R. B.; Grieg, N.; Kim, A.; De Costa, B. R.; Rice, K. C.; Carroll, F. I.; Pert, A. Cocaine and GBR12909 produce equivalent motoric responses at different occupancy of the dopamine transporter. Pharmacol. Biochem. Behav. 1992, 43, 1135-1142.
188. Volkow, N. D.; Ding, Y. S.; Fowler, J. S.; Wang, G. J.; Logan, J.; Gatley, S. J.; Schlyer, D. J.; Pappas, N. A new PET ligand for the dopamine transporter: Studies in the human brain. J. Nucl. Med. 1995, 36, 2162-2168.
189. Volkow, N. D.; Wang, G. J.; Fowler, J. S.; Gatley, S. J.; Ding, Y. S.; Logan, J.; Dewey, S. L.; Hitzemann, R.; Lieberman, J. Relationship between psychostimulant-induced "high" and dopamine transporter occupancy. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 10388-10392.
190. Volkow, N. D.; Wang, G.-J.; Fischman, M. W.; Foltin, R. W.; Fowler, J. S.; Abumrad, N. N.; Vitkun, S.; Logan, J.; Gatley, S. J.; Pappas, N.; Hitzemann, R.; Shea, C. E. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 1997, 386, 827-833.
191. 11C]WIN 35,428. Synapse 1993, 15, 130-142.
192. Fulco, C. E.; Liverman, C. T.; Earley, L. E. Development of Medications for the Treatment of Opiate and Cocaine Addictions: Issues for the Government and Private Sector; National Academy Press: Washington, DC, 1995.
193. Committee on Opportunities in Drug Abuse Research; Division of Neuroscience and Behavioral Health; Institute of Medicine. Pathways of Addiction: Opportunities in Drug Abuse Research; National Academy Press: Washington, DC, 1996.
194. Douglass, J.; McKinzie, A. A.; Couceyro, P. PCR differential display identifies a rat brain mRNA that is transcriptionally regulated by cocaine and amphetamine. J. Neurosci. 1995, 15, 2471-2481.
195. Berhow, M. T.; Russell, D. S.; Terwilliger, R. Z.; Beitner-Johnson, D.; Self, D. W.; Lindsay, R. M.; Nestler, E. J. Influence of neurotrophic factors on morphine-and cocaine-induced biochemical changes in the mesolimbic dopamine system. Neuroscience 1995, 68, 969-979.
196. Zetterstrom, R. H.; Solomin, L.; Jansson, L.; Hoffer, B. J.; Olson, L.; Perlmann, T. Dopamine neuron agenesis in Nurr1-deficient mice. Science 1997, 276, 248-250.